Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29607076 | 0.79 | CHRNA7 (0.38) | CHRNA7ALDH1A1CHRNA4CHRM2CHRM1 | |
| SCHEMBL1057440 | 0.75 | CHRNA7 (0.48) | CHRNA7ALDH1A1CHRNA4CHRM2CHRM1 | |
| SCHEMBL18268169 | 0.75 | CHRNA7 (0.42) | CHRNA7ALDH1A1CHRNA4CHRM2CHRM1 | |
| SCHEMBL10917945 | 0.75 | CHRNA7 (0.42) | CHRNA7ALDH1A1CHRNA4CHRM2CHRM1 | |
| SCHEMBL10915261 | 0.75 | CHRNA7 (0.42) | CHRNA7ALDH1A1CHRNA4CHRM2CHRM1 | |
| SCHEMBL18268167 | 0.75 | CHRNA7 (0.42) | CHRNA7ALDH1A1CHRNA4CHRM2CHRM1 | |
| SCHEMBL415807 | 0.75 | CHRNA7 (0.42) | CHRNA7ALDH1A1CHRNA4CHRM2CHRM1 | |
| SCHEMBL14027182 | 0.75 | CHRNA7 (0.42) | CHRNA7CHRNA4CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL10978368 | 0.73 | CHRNA7 (0.41) | CHRNA7ALDH1A1CHRNA4CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL2418790 | 0.73 | CHRNA7 (0.41) | CHRNA7ALDH1A1CHRNA4CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0102283-B1 | PROCESS FOR THE PREPARATION OF QUINUCLIDINE DERIVATIVES SUBSTITUTED IN POSITION 3 | PHARMUKA LABORATOIRES (FR) | 1986-12-03 | — | — | EP | claimed |
| US-4546185-A | REACTING 3-METHYLENE QUINUCLIDINE WITH AN ALUMINUM HYDRIDE USING SOLVENT AND TRANSITION METAL CATALYST; INSITU REACTING WITH AN ESTERTHEN HALOGENATING AGENT | PHARMUKA LABORATOIRES (FR) | 1985-10-08 | — | — | US | claimed |
| EP-2109609-B1 | NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | PF MEDICAMENT (FR) | 2013-06-12 | — | — | EP | disclosed |
| US-8304545-B2 | Quinuclidine derivative useful in the preparation of mequitazine | PIERRE FABRE MEDICAMENT (FR) | 2012-11-06 | — | — | US | disclosed |
| US-8158784-B2 | Quinuclidine derivative useful in the preparation of mequitazine | PIERRE FABRE MEDICAMENT (FR) | 2012-04-17 | — | — | US | disclosed |
| US-20120088917-A1 | NEW QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | MIOSKOWSKI CHARLES (FR) | 2012-04-12 | — | — | US | disclosed |
| US-8048893-B2 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA SA (FR) | 2011-11-01 | — | — | US | disclosed |
| CN-102174017-A | Pyrazolyl derivatives in the form of drugs for treating acute or chronic neuronal regressions | AVENTIS PHARMA SA | 2011-09-07 | — | — | CN | disclosed |
| US-20100105897-A1 | NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | PIERRE FABRE MEDICAMENT (FR) | 2010-04-29 | — | — | US | disclosed |
| EP-2109609-A1 | NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | Pierre Fabre Medicament (FR) | 2009-10-21 | — | — | EP | disclosed |
| US-20090170833-A1 | PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2009-07-02 | — | — | US | disclosed |
| WO-2005051917-A1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA S.A. (FR) | 2005-06-09 | — | — | WO | disclosed |
| EP-1037891-B1 | METHOD FOR PREPARING MEQUITAZINE AND NOVEL SYNTHESIS INTERMEDIATE | PF MEDICAMENT (FR) | 2002-04-10 | — | — | EP | disclosed |
| EP-1037891-A1 | METHOD FOR PREPARING MEQUITAZINE AND NOVEL SYNTHESIS INTERMEDIATE | PIERRE FABRE MEDICAMENT (FR) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999029692-A1 | METHOD FOR PREPARING MEQUITAZINE AND NOVEL SYNTHESIS INTERMEDIATE | PIERRE FABRE MEDICAMENT (FR) | 1999-06-17 | — | — | WO | disclosed |
| US-4546185-A | REACTING 3-METHYLENE QUINUCLIDINE WITH AN ALUMINUM HYDRIDE USING SOLVENT AND TRANSITION METAL CATALYST; INSITU REACTING WITH AN ESTERTHEN HALOGENATING AGENT | PHARMUKA LABORATOIRES (FR) | 1985-10-08 | — | — | US | disclosed |
| US-4525475-A | Prevention of thrombolic disorder with imidazole derivatives and salts thereof | THOROGOOD PETER B (GB) | 1985-06-25 | — | — | US | disclosed |
| EP-0015002-B1 | 1-SUBSTITUTED IMIDAZOLES, AND SALTS THEREOF, A METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS THEREOF | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-04-18 | — | — | EP | disclosed |
| US-4328234-A | Imidazole derivatives and salts thereof and pharmaceutical formulations useful in thrombo-embolic disorders | BURROUGHS WELLCOME CO. (US) | 1982-05-04 | — | — | US | disclosed |
| EP-0015002-A1 | 1-substituted imidazoles, and salts thereof, a method for their preparation and pharmaceutical formulations thereof | THE WELLCOME FOUNDATION LIMITED (GB) | 1980-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170833-A1 | PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | C1R, CBR3, C3AR1 | CHRNA7 65/4885ALDH1A1 2487/4885CHRNA4 572/4885 |
| US-20120088917-A1 | NEW QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | AZI2, NQO2, SIRT5 | CHRNA7 66/4885ALDH1A1 633/4885CHRNA4 102/4885 |
| US-20100105897-A1 | NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | AZI2, NQO2, SIRT5 | CHRNA7 82/4885ALDH1A1 575/4885CHRNA4 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.